← Back to patent-cliff list
Lacripep
Tier C — Watch / tradeLacripep
Tearsolutions Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Eye proteins
Brand：Lacripep
Indications (approved)：神经营养性角膜炎, 角膜疾病, Sjögren's syndrome, Dry eye disease
Regional status
US
Phase II
2017-06-30
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lacripep?
Approved indications include: 神经营养性角膜炎, 角膜疾病, Sjögren's syndrome, Dry eye disease.
When does the Lacripep patent expire?
No public expiry year is available for Lacripep yet; this page updates once verified.
How do I get a quote for Lacripep intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09